ScholarIQanswers from OpenAlex & ORCID
Uli C. Broedl
ResearcherPublications, citations & collaboration network
Uli C. Broedl is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Uli C. Broedl have?
ScholarIQindexed works
Uli C. Broedl has 153 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Uli C. Broedl have?
ScholarIQcitation count
Uli C. Broedl has 33,090 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Uli C. Broedl?
ScholarIQh-index
Uli C. Broedl has an h-index of 62 in OpenAlex.
What is the i10-index of Uli C. Broedl?
ScholarIQi10-index
Uli C. Broedl has an i10-index of 104 in OpenAlex.
What is the ORCID of Uli C. Broedl?
ScholarIQorcid
The ORCID for Uli C. Broedl is on the source record.
What is the OpenAlex record for Uli C. Broedl?
ScholarIQopenalex
The OpenAlex for Uli C. Broedl is on the source record.
What are the most-cited papers on Uli C. Broedl?
ScholarIQmost cited works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, M Maione, Vesta Lai, Alana Lee, Nora Fagan, Hans J. Woerle, Odd Erik Johansen, Uli C. Broedl, Maximilian von Eynatten
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C. Broedl, Hans‐Juergen Woerle
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial
David Fitchett, Bernard Zinman, Christoph Wanner, John M. Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi